Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
出版年份 2017 全文链接
标题
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications
作者
关键词
-
出版物
NATURE REVIEWS DRUG DISCOVERY
Volume 17, Issue 1, Pages 19-33
出版商
Springer Nature
发表日期
2017-10-27
DOI
10.1038/nrd.2017.194
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase II and phase III failures: 2013–2015
- (2016) Richard K. Harrison NATURE REVIEWS DRUG DISCOVERY
- Trends in clinical success rates
- (2016) Katarzyna Smietana et al. NATURE REVIEWS DRUG DISCOVERY
- A comprehensive map of molecular drug targets
- (2016) Rita Santos et al. NATURE REVIEWS DRUG DISCOVERY
- Solanezumab and the amyloid hypothesis for Alzheimer’s disease
- (2016) David G Le Couteur et al. BMJ-British Medical Journal
- Solanezumab and the amyloid hypothesis for Alzheimer’s disease
- (2016) David G Le Couteur et al. BMJ-British Medical Journal
- Toxicology Strategies for Drug Discovery: Present and Future
- (2015) Eric A. G. Blomme et al. CHEMICAL RESEARCH IN TOXICOLOGY
- Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials
- (2015) Andreas Soejitno et al. CNS DRUGS
- Twenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use
- (2015) Guido Antonelli et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Small-molecule inhibitors for autoimmune arthritis: Success, failure and the future
- (2015) Ling-Jun Ho et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Animal models of rheumatoid arthritis: How informative are they?
- (2015) Kay McNamee et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Targeting cancer with kinase inhibitors
- (2015) Stefan Gross et al. JOURNAL OF CLINICAL INVESTIGATION
- The support of human genetic evidence for approved drug indications
- (2015) Matthew R Nelson et al. NATURE GENETICS
- Translational value of mouse models in oncology drug development
- (2015) Stephen E Gould et al. NATURE MEDICINE
- Why is it hard to terminate failing projects in pharmaceutical R&D?
- (2015) Richard W. Peck et al. NATURE REVIEWS DRUG DISCOVERY
- An analysis of the attrition of drug candidates from four major pharmaceutical companies
- (2015) Michael J. Waring et al. NATURE REVIEWS DRUG DISCOVERY
- A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease
- (2014) Eric Karran et al. ANNALS OF NEUROLOGY
- Can we unlock the potential of IGF-1R inhibition in cancer therapy?
- (2014) Helen King et al. CANCER TREATMENT REVIEWS
- Addressing toxicity risk when designing and selecting compounds in early drug discovery
- (2014) Matthew D. Segall et al. DRUG DISCOVERY TODAY
- Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus
- (2014) Ivan Gentile et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Clinical development success rates for investigational drugs
- (2014) Michael Hay et al. NATURE BIOTECHNOLOGY
- Improving and Accelerating Drug Development for Nervous System Disorders
- (2014) Diana E. Pankevich et al. NEURON
- TNF inhibitors – Mechanisms of action, approved and off-label indications
- (2014) Grzegorz Cessak et al. Pharmacological Reports
- The therapeutics of Alzheimer's disease: Where we stand and where we are heading
- (2013) Dennis J. Selkoe ANNALS OF NEUROLOGY
- Animal models of CNS disorders
- (2013) Paul McGonigle BIOCHEMICAL PHARMACOLOGY
- Recent failures in antiatherosclerotic drug development
- (2013) Robert M. Stoekenbroek et al. CURRENT OPINION IN LIPIDOLOGY
- Targeting leukotriene B4in inflammation
- (2013) Antonio Di Gennaro et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- ACAT Inhibitors: The Search for Novel Cholesterol Lowering Agents
- (2013) Palash Pal et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Does size matter in R&D productivity? If not, what does?
- (2013) Michael Ringel et al. NATURE REVIEWS DRUG DISCOVERY
- Novelty in the target landscape of the pharmaceutical industry
- (2013) Pankaj Agarwal et al. NATURE REVIEWS DRUG DISCOVERY
- Phase II and Phase III attrition rates 2011–2012
- (2013) John Arrowsmith et al. NATURE REVIEWS DRUG DISCOVERY
- Validating therapeutic targets through human genetics
- (2013) Robert M. Plenge et al. NATURE REVIEWS DRUG DISCOVERY
- Orphan drug development: an economically viable strategy for biopharma R&D
- (2012) Kiran N. Meekings et al. DRUG DISCOVERY TODAY
- Aliskiren, the first direct renin inhibitor for treatment of hypertension: The path of its development
- (2012) M Jadhav et al. Journal of Postgraduate Medicine
- Rare diseases and orphan drugs
- (2012) Irena Melnikova NATURE REVIEWS DRUG DISCOVERY
- Reducing safety-related drug attrition: the use of in vitro pharmacological profiling
- (2012) Joanne Bowes et al. NATURE REVIEWS DRUG DISCOVERY
- Diagnosing the decline in pharmaceutical R&D efficiency
- (2012) Jack W. Scannell et al. NATURE REVIEWS DRUG DISCOVERY
- Getting pharmaceutical R&D back on target
- (2011) Mark E Bunnage Nature Chemical Biology
- The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
- (2011) Eric Karran et al. NATURE REVIEWS DRUG DISCOVERY
- Phase II failures: 2008–2010
- (2011) John Arrowsmith NATURE REVIEWS DRUG DISCOVERY
- The productivity crisis in pharmaceutical R&D
- (2011) Fabio Pammolli et al. NATURE REVIEWS DRUG DISCOVERY
- Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
- (2010) J A DiMasi et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- 5-Lipoxygenase inhibitors: a review of recent developments and patents
- (2010) Carlo Pergola et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Anticancer drug development: the grand challenges
- (2010) William N. Hait NATURE REVIEWS DRUG DISCOVERY
- Modelling and PBPK Simulation in Drug Discovery
- (2009) Hannah M. Jones et al. AAPS Journal
- Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis
- (2009) Stanley B. Cohen et al. ARTHRITIS AND RHEUMATISM
- Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: Results of two randomized, double-blind, placebo-controlled clinical studies
- (2009) Nemanja Damjanov et al. ARTHRITIS AND RHEUMATISM
- Comprehensive Assessment of ADMET Risks in Drug Discovery
- (2009) Jianling Wang CURRENT PHARMACEUTICAL DESIGN
- ACAT Inhibition and Progression of Carotid Atherosclerosis in Patients With Familial Hypercholesterolemia
- (2009) Marijn C. Meuwese et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Aliskiren: the first renin inhibitor for clinical treatment
- (2008) Chris Jensen et al. NATURE REVIEWS DRUG DISCOVERY
- Muscarinic acetylcholine receptors as CNS drug targets
- (2007) Christopher J. Langmead et al. PHARMACOLOGY & THERAPEUTICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started